Menu

rss
Heart 95:970-975 doi:10.1136/hrt.2008.153114
  • Original article
  • Interventional cardiology

Comparison of inflammatory markers and angiographic outcomes after implantation of sirolimus and paclitaxel-eluting stents

  1. W C Kang1,
  2. T H Ahn1,
  3. C I Moon1,
  4. S H Han1,
  5. E K Shin1,
  6. J-S Kim2,
  7. Y-G Ko2,
  8. D Choi2,
  9. Y Jang2,
  10. B-K Kim3,
  11. S J Oh3,
  12. D W Jeon3,
  13. J-Y Yang3
  1. 1
    Division of Cardiology, Gachon University of Medicine and Science, Incheon, Korea
  2. 2
    Division of Cardiology, Yonsei University College of Medicine, Seoul, Korea
  3. 3
    NHIC Ilsan Hospital, Koyang, Korea
  1. Dr Woong Chol Kang, Cardiology, Gil Medical Center, Gachon University of Medicine and Science, 1198 Kuwol-dong, Namdong-gu, Incheon, Korea 405-760; kangwch{at}gilhospital.com
  • Accepted 26 August 2008
  • Published Online First 4 September 2008

Abstract

Objective: We compared the degree of systemic inflammation and its relation to the angiographic outcomes after drug-eluting stent (DES) implantations.

Methods: We implanted a single DES in 79 stable angina patients (50 men; 60.4 (9.5) years of age; sirolimus-eluting stent (SES), n = 38; paclitaxel-eluting stent (PES), n = 41). The high-sensitivity C-reactive protein (hs-CRP) and interleukin 6 (IL-6) levels were determined before and at 24 hours, 72 hours, and 4 weeks after the percutaneous coronary intervention (PCI). An angiography and intravascular ultrasound (IVUS) were performed.

Results: The hs-CRP and IL-6 levels at baseline did not differ between the two groups. The hs-CRP increased significantly from baseline at 24 hours and 72 hours after the PCI in both groups and there was a significant increase in the IL-6 level at 24 hours after the PCI in both groups. However, there was no significant difference between the two groups in any of the hs-CRP or IL-6 measurements. At follow-up, the late lumen loss was significantly higher in the PES group than in the SES group (0.57 (0.56) mm vs 0.28 (0.58) mm, respectively, p = 0.020). The neointimal hyperplasia (NIH) volume in the PES group was significantly higher than that in the SES group (23.1 (22.7) vs 3.8 (7.1) mm3, respectively, p = 0.000). The percentage luminal volume reduction was higher in the PES group than in the SES group (18.9 vs 3.9%, p = 0.002). The absolute values or change in the inflammatory markers did not correlate with the NIH or stent volume reduction.

Conclusions: Our study showed that the benefits obtained from the SES, which reduce neointimal proliferation, are not probably mediated by the attenuation of the systemic inflammatory markers hs-CRP or IL-6.

Footnotes

  • See Editorial, p 957

  • Funding: None.

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. hrt.2008.153114v1
    2. 95/12/970 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Heart.
View free sample issue >>

Free archive
The full back archive is now available for Heart. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.